Dermagenics

Dermagenics is a biotechnology and medical-grade skincare company focused on regenerative medicine for dermatological applications. The company's core technology centers on a proprietary signaling platform that stimulates the skin's endogenous production of growth factors to repair damage and reverse signs of aging. Dermagenics has advanced its lead therapeutic candidate into Phase 2 clinical trials for the treatment of actinic keratosis, a precursor to skin cancer. In addition to its clinical pipeline, the company markets a range of commercial products for skin rejuvenation, wound healing, and post-surgical recovery. The company's approach emphasizes natural skin repair without the use of exogenous proteins or harsh chemicals.